Quince Therapeutics, Inc. Insider Trading Arrangements
Rule 10b5-1 and other trading arrangements that directors and officers adopted or terminated, as each 10-Q and 10-K tags them (Item 408(a)), newest report first.
- 2026-04-10: Individual Charles Ryan; Title President; Arrangement Rule 10b5-1; Adopted December 22, 2025.
- 2026-04-10: Individual Brendan Hannah; Title Chief Operating Officer; Arrangement Rule 10b5-1; Adopted December 22, 2025.
- 2026-04-10: .
- 2026-04-10: .
| Report filed | Individual | Title | Arrangement | Adopted | Terminated | Expires or duration | Securities covered |
|---|---|---|---|---|---|---|---|
| 2026-04-10 10-K | Charles Ryan | President | Rule 10b5-1 | December 22, 2025 | April 6, 2027 P470D | ||
| 2026-04-10 10-K | Brendan Hannah | Chief Operating Officer | Rule 10b5-1 | December 22, 2025 | April 6, 2027 P470D | 500,000 | |
| 2026-04-10 10-K | 122,461 | ||||||
| 2026-04-10 10-K | 527,290 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |